A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day on days 1, 2,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2013
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682338/
https://ncbi.nlm.nih.gov/pubmed/23591789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-466706
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi